"The U.S. Food and Drug Administration today approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.
Multiple myeloma is a form of blood cancer that p"...
Colony-stimulating factors are glycoproteins which act on hematopoietic cells by binding to specific cell surface receptors and stimulating proliferation‚ differentiation commitment‚ and some end-cell functional activation.
Endogenous G-CSF is a lineage specific colony-stimulating factor which is produced by monocytes‚ fibroblasts, and endothelial cells. G-CSF regulates the production of neutrophils within the bone marrow and affects neutrophil progenitor proliferation‚2‚3 differentiation,2‚4 and selected end-cell functional activation (including enhanced phagocytic ability‚5 priming of the cellular metabolism associated with respiratory burst‚6 antibody dependent killing,7 and the increased expression of some functions associated with cell surface antigens8). G-CSF is not species specific and has been shown to have minimal direct in vivo or in vitro effects on the production of hematopoietic cell types other than the neutrophil lineage.
Filgrastim was administered to monkeys‚ dogs‚ hamsters‚ rats‚ and mice as part of a preclinical toxicology program which included single-dose acute‚ repeated-dose subacute‚ subchronic‚ and chronic studies. Single-dose administration of Filgrastim by the oral‚ intravenous (IV)‚ subcutaneous (SC)‚ or intraperitoneal (IP) routes resulted in no significant toxicity in mice‚ rats‚ hamsters‚ or monkeys. Although no deaths were observed in mice‚ rats‚ or monkeys at dose levels up to 3450 mcg/kg or in hamsters using single doses up to approximately 860 mcg/kg‚ deaths were observed in a subchronic (13- week) study in monkeys. In this study‚ evidence of neurological symptoms was seen in monkeys treated with doses of Filgrastim greater than 1150 mcg/kg/day for up to 18 days. Deaths were seen in 5 of the 8 treated animals and were associated with 15- to 28-fold increases in peripheral leukocyte counts‚ and neutrophil-infiltrated hemorrhagic foci were seen in both the cerebrum and cerebellum. In contrast‚ no monkeys died following 13 weeks of daily IV administration of Filgrastim at a dose level of 115 mcg/kg. In an ensuing 52-week study‚ one 115 mcg/kg dosed female monkey died after 18 weeks of daily IV administration of Filgrastim. Death was attributed to cardiopulmonary insufficiency.
In subacute‚ repeated-dose studies‚ changes observed were attributable to the expected pharmacological actions of Filgrastim (ie‚ dose-dependent increases in white cell counts‚ increased circulating segmented neutrophils‚ and increased myeloid: erythroid ratio in bone marrow). In all species‚ histopathologic examination of the liver and spleen revealed evidence of ongoing extramedullary granulopoiesis; increased spleen weights were seen in all species and appeared to be dose-related. A dose-dependent increase in serum alkaline phosphatase was observed in rats‚ and may reflect increased activity of osteoblasts and osteoclasts. Changes in serum chemistry values were reversible following discontinuation of treatment.
In rats treated at doses of 1150 mcg/kg/day for 4 weeks (5 of 32 animals) and for 13 weeks at doses of 100 mcg/kg/day (4 of 32 animals) and 500 mcg/kg/day (6 of 32 animals)‚ articular swelling of the hind legs was observed. Some degree of hind leg dysfunction was also observed; however‚ symptoms reversed following cessation of dosing. In rats‚ osteoclasis and osteoanagenesis were found in the femur‚ humerus‚ coccyx‚ and hind legs (where they were accompanied by synovitis) after IV treatment for 4 weeks (115 to 1150 mcg/kg/day)‚ and in the sternum after IV treatment for 13 weeks (115 to 575 mcg/kg/day). These effects reversed to normal within 4 to 5 weeks following cessation of treatment.
In the 52-week chronic‚ repeated-dose studies performed in rats (IP injection up to 57.5 mcg/kg/day)‚ and cynomolgus monkeys (IV injection of up to 115 mcg/kg/day)‚ changes observed were similar to those noted in the subacute studies. Expected pharmacological actions of Filgrastim included dose-dependent increases in white cell
counts‚ increased circulating segmented neutrophils and alkaline phosphatase levels‚ and increased myeloid:erythroid ratios in the bone marrow. Decreases in platelet counts were also noted in primates. In no animals tested were hemorrhagic complications observed. Rats displayed dose-related swelling of the hind limb‚ accompanied by some degree of hind limb dysfunction; osteopathy was noted microscopically. Enlarged spleens (both species) and livers (monkeys)‚ reflective of ongoing extramedullary granulopoiesis‚ as well as myeloid hyperplasia of the bone marrow‚ were observed in a dose-dependent manner.
Pharmacologic Effects of NEUPOGEN®
In phase 1 studies involving 96 patients with various nonmyeloid malignancies‚ NEUPOGEN® administration resulted in a dose-dependent increase in circulating neutrophil counts over the dose range of 1 to 70 mcg/kg/day.9-11 This increase in neutrophil counts was observed whether NEUPOGEN® was administered IV (1 to 70 mcg/kg twice daily)‚9 SC (1 to 3 mcg/kg once daily)‚11 or by continuous SC infusion (3 to 11 mcg/kg/day).10 With discontinuation of NEUPOGEN® therapy‚ neutrophil counts returned to baseline‚ in most cases within 4 days. Isolated neutrophils displayed normal phagocytic (measured by zymosan-stimulated chemoluminescence) and chemotactic (measured by migration under agarose using N-formyl-methionyl-leucyl-phenylalanine [fMLP] as the chemotaxin) activity in vitro.
The absolute monocyte count was reported to increase in a dose-dependent manner in most patients receiving NEUPOGEN®; however‚ the percentage of monocytes in the differential count remained within the normal range. In all studies to date‚ absolute counts of both eosinophils and basophils did not change and were within the normal range following administration of NEUPOGEN®. Increases in lymphocyte counts following NEUPOGEN® administration have been reported in some normal subjects and cancer patients.
White blood cell (WBC) differentials obtained during clinical trials have demonstrated a shift towards earlier granulocyte progenitor cells (left shift)‚ including the appearance of promyelocytes and myeloblasts‚ usually during neutrophil recovery following the chemotherapy-induced nadir. In addition‚ Dohle bodies‚ increased granulocyte granulation‚ and hypersegmented neutrophils have been observed. Such changes were transient and were not associated with clinical sequelae, nor were they necessarily associated with infection.
Absorption and clearance of NEUPOGEN® follows first-order pharmacokinetic modeling without apparent concentration dependence. A positive linear correlation occurred between the parenteral dose and both the serum concentration and area under the concentration-time curves. Continuous IV infusion of 20 mcg/kg of NEUPOGEN® over 24 hours resulted in mean and median serum concentrations of approximately 48 and 56 ng/mL‚ respectively. Subcutaneous administration of 3.45 mcg/kg and 11.5 mcg/kg resulted in maximum serum concentrations of 4 and 49 ng/mL‚ respectively‚ within 2 to 8 hours. The volume of distribution averaged 150 mL/kg in both normal subjects and cancer patients. The elimination half-life‚ in both normal subjects and cancer patients‚ was approximately 3.5 hours. Clearance rates of NEUPOGEN® were approximately 0.5 to 0.7 mL/minute/kg. Single parenteral doses or daily IV doses‚ over a 14-day period‚ resulted in comparable half-lives. The half-lives were similar for IV administration (231 minutes‚ following doses of 34.5 mcg/kg) and for SC administration (210 minutes‚ following NEUPOGEN® doses of 3.45 mcg/kg). Continuous 24-hour IV infusions of 20 mcg/kg over an 11- to 20-day period produced steady-state serum concentrations of NEUPOGEN® with no evidence of drug accumulation over the time period investigated. Pharmacokinetic data in geriatric patients ( ≥ 65 years) are not available.
Cancer Patients Receiving Myelosuppressive Chemotherapy
NEUPOGEN® has been shown to be safe and effective in accelerating the recovery of neutrophil counts following a variety of chemotherapy regimens. In a phase 3 clinical trial in small cell lung cancer‚ patients received SC administration of NEUPOGEN® (4 to 8 mcg/kg/day‚ days 4 to 17) or placebo. In this study‚ the benefits of NEUPOGEN® therapy were shown to be prevention of infection as manifested by febrile neutropenia‚ decreased hospitalization‚ and decreased IV antibiotic usage. No difference in survival or disease progression was demonstrated.
In the phase 3‚ randomized‚ double-blind‚ placebo-controlled trial conducted in patients with small cell lung cancer‚ patients were randomized to receive NEUPOGEN® (n = 99) or placebo (n = 111) starting on day 4‚ after receiving standard dose chemotherapy with cyclophosphamide‚ doxorubicin‚ and etoposide. A total of 210 patients were evaluated for efficacy and 207 evaluated for safety. Treatment with NEUPOGEN® resulted in a clinically and statistically significant reduction in the incidence of infection‚ as manifested by febrile neutropenia; the incidence of at least one infection over all cycles of chemotherapy was 76% (84/111) for placebo-treated patients‚ versus 40% (40/99) for NEUPOGEN®-treated patients (p < 0.001). The following secondary analyses were also performed. The requirements for in-patient hospitalization and antibiotic use were also significantly decreased during the first cycle of chemotherapy; incidence of hospitalization was 69% (77/111) for placebo-treated patients in cycle 1‚ versus 52% (51/99) for NEUPOGEN®-treated patients (p = 0.032). The incidence of IV antibiotic usage was 60% (67/111) for placebo-treated patients in cycle 1‚ versus 38% (38/99) for NEUPOGEN®-treated patients (p = 0.003). The incidence‚ severity‚ and duration of severe neutropenia (absolute neutrophil count [ANC] < 500/mm³) following chemotherapy were all significantly reduced. The incidence of severe neutropenia in cycle 1 was 84% (83/99) for patients receiving NEUPOGEN® versus 96% (106/110) for patients receiving placebo (p = 0.004). Over all cycles‚ patients randomized to NEUPOGEN® had a 57% (286/500 cycles) rate of severe neutropenia versus 77% (416/543 cycles) for patients randomized to placebo. The median duration of severe neutropenia in cycle 1 was reduced from 6 days (range 0 to 10 days) for patients receiving placebo to 2 days (range 0 to 9 days) for patients receiving NEUPOGEN® (p < 0.001). The mean duration of neutropenia in cycle 1 was 5.64 ±2.27 days for patients receiving placebo versus 2.44 ±1.90 days for patients receiving NEUPOGEN®. Over all cycles‚ the median duration of neutropenia was 3 days for patients randomized to placebo versus 1 day for patients randomized to NEUPOGEN®. The median severity of neutropenia (as measured by ANC nadir) was 72/mm³ (range 0/mm³ to 7912/mm³) in cycle 1 for patients receiving NEUPOGEN® versus 38/mm³ (range 0/mm³ to 9520/mm³) for patients receiving placebo (p = 0.012). The mean severity of neutropenia in cycle 1 was 496/mm³ ±1382/mm³ for patients receiving NEUPOGEN® versus 204/mm³ ±953/mm³ for patients receiving placebo. Over all cycles‚ the ANC nadir for patients randomized to NEUPOGEN® was 403/mm³‚ versus 161/mm³ for patients randomized to placebo. Administration of NEUPOGEN® resulted in an earlier ANC nadir following chemotherapy than was experienced by patients receiving placebo (day 10 vs day 12). NEUPOGEN® was well tolerated when given SC daily at doses of 4 to 8 mcg/kg for up to 14 consecutive days following each cycle of chemotherapy (see ADVERSE REACTIONS).
Several other phase ½ studies‚ which did not directly measure the incidence of infection‚ but which did measure increases in neutrophils‚ support the efficacy of NEUPOGEN®. The regimens are presented to provide some background on the clinical experience with NEUPOGEN®. No claim regarding the safety or efficacy of the chemotherapy regimens is made. The effects of NEUPOGEN® on tumor growth or on the anti-tumor activity of the chemotherapy were not assessed. The doses of NEUPOGEN® used in these studies are considerably greater than those found to be effective in the phase 3 study described above. Such phase ½ studies are summarized in the following table.
|Type of Malignancy||Regimen||Chemotherapy Dose||No. Pts.||Trial Phase||NEUPOGEN® Daily Dosagea|
|Small Cell Lung Cancer||Cyclophosphamide Doxorubicin Etoposide||1 g/m²/day
50 mg/m²/day 120 mg/m²/day x 3
q 21 days
|210||3||4 — 8 mcg/kg SC
days 4 — 17
|Small Cell Lung Cancer11||Ifosfamide Doxorubicin Etoposide
120 mg/m²/day x 3 8 g/m²/day
q 21 days
|12||1 /2||5.75 - 46 mcg/kg IV
days 4 — 17
|Urothelial Cancer12||Methotrexate Vinblastine Doxorubicin Cisplatin||30 mg/m²/day x 2
3 mg/m²/day x 2
70 mg/m²/day q 28 days
|40||½||3.45 — 69 mcg/kg IV
days 4 — 11
|Various Nonmyeloid Malignancies13||Cyclophosphamide Etoposide
|2.5 g/m²/day x 2
500 mg/m²/day x 3
50 mg/m²/day x 3
q 28 days
|18||½||23 — 69 mcg/kgb IV
days 8 — 28
|Breast/Ovarian Cancer14||Doxorubicinc||75 mg/m²
q 14 days
|21||2||11.5 mcg/kg IV
days 2 — 9 5.75 mcg/kg IV
days 10 — 12
|Neuroblastoma||Cyclophosphamide Doxorubicin Cisplatin||150 mg/m² x 7
q 28 days (cycles 1,3,5)
|12||2||5.45 — 17.25 mcg/kg SC
days 6 — 19
|a NEUPOGEN® doses were those that accelerated
neutrophil production. Doses which provided no additional acceleration beyond
that achieved at the next lower dose are not reported.
b Lowest dose(s) tested in the study.
c Patients received doxorubicin at either 75‚ 100‚ 125‚ or 150 mg/m².
d Cycles 2‚6 = cyclophosphamide 150 mg/m² x 7 and etoposide 280 mg/m² x 3. Cycle 4 = cisplatin 90 mg/m² x 1 and etoposide 280 mg/m² x 3.
Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy
In a randomized, double-blind‚ placebo-controlled‚ multi-center‚ phase 3 clinical trial‚ 521 patients (median age 54‚ range 16 to 89 years) were treated for de novo acute myeloid leukemia (AML). Following a standard induction chemotherapy regimen comprising daunorubicin, cytosine arabinoside, and etoposide15 (DAV 3+7+5), patients received either NEUPOGEN® at 5 mcg/kg/day or placebo, SC, from 24 hours after the last dose of chemotherapy until neutrophil recovery (ANC 1000/mm³ for 3 consecutive days or 10,000/mm³ for 1 day) or for a maximum of 35 days.
Treatment with NEUPOGEN® significantly reduced the median time to ANC recovery and the median duration of fever, antibiotic use, and hospitalization following induction chemotherapy. In the NEUPOGEN®-treated group‚ the median time from initiation of chemotherapy to ANC recovery (ANC ≥ 500/mm³) was 20 days (vs 25 days in the control group, p = 0.0001), the median duration of fever was reduced by 1.5 days (p = 0.009), and there were statistically significant reductions in the durations of IV antibiotic use and hospitalization. During consolidation therapy (DAV 2+5+5), patients treated with NEUPOGEN® also experienced significant reductions in the incidence of severe neutropenia, time to neutrophil recovery, the incidence and duration of fever, and the durations of IV antibiotic use and hospitalization. Patients treated with a further course of standard (DAV 2+5+5) or high-dose cytosine arabinoside consolidation also experienced significant reductions in the duration of neutropenia.
There were no statistically significant differences between NEUPOGEN® and placebo groups in complete remission rate (69% NEUPOGEN® vs 68% placebo, p = 0.77), disease-free survival (median 342 days NEUPOGEN® [n = 178], 322 days placebo [n = 177], p = 0.99), time to progression of all randomized patients (median 165 days NEUPOGEN®, 186 days placebo, p = 0.87), or overall survival (median 380 days NEUPOGEN®, 425 days placebo, p = 0.83).
Cancer Patients Receiving Bone Marrow Transplant
In two separate randomized‚ controlled trials‚ patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) were treated with myeloablative chemotherapy and autologous bone marrow transplantation (ABMT). In one study (n = 54)‚ NEUPOGEN® was administered at doses of 10 or 30 mcg/kg/day; a third treatment group in this study received no NEUPOGEN®. A statistically significant reduction in the median number of days of severe neutropenia (ANC < 500/mm³) occurred in the NEUPOGEN®-treated group versus the control group (23 days in the control group‚ 11 days in the 10 mcg/kg/day group‚ and 14 days in the 30 mcg/kg/day group [11 days in the combined treatment groups‚ p = 0.004]). In the second study (n = 44‚ 43 patients evaluable)‚ NEUPOGEN® was administered at doses of 10 or 20 mcg/kg/day; a third treatment group in this study received no NEUPOGEN®. A statistically significant reduction in the median number of days of severe neutropenia occurred in the NEUPOGEN®-treated group versus the control group (21.5 days in the control group and 10 days in both treatment groups‚ p < 0.001). The number of days of febrile neutropenia was also reduced significantly in this study (13.5 days in the control group‚ 5 days in the 10 mcg/kg/day group‚ and 5.5 days in the 20 mcg/kg/day group [5 days in the combined treatment groups‚ p < 0.0001]). Reductions in the number of days of hospitalization and antibiotic use were also seen‚ although these reductions were not statistically significant. There were no effects on red blood cell or platelet levels.
In a randomized‚ placebo-controlled trial‚ 70 patients with myeloid and nonmyeloid malignancies were treated with myeloablative therapy and allogeneic bone marrow transplant followed by 300 mcg/m²/day of a Filgrastim product. A statistically significant reduction in the median number of days of severe neutropenia occurred in the treated group versus the control group (19 days in the control group and 15 days in the treatment group‚ p < 0.001) and time to recovery of ANC to ≥ 500/mm³ (21 days in the control group and 16 days in the treatment group‚ p < 0.001).
In three nonrandomized studies (n = 119)‚ patients received ABMT and treatment with NEUPOGEN®. One study (n = 45) involved patients with breast cancer and malignant melanoma. A second study (n = 39) involved patients with HD. The third study (n = 35) involved patients with NHL‚ acute lymphoblastic leukemia (ALL)‚ and germ cell tumor. In these studies‚ the recovery of the ANC to ≥ 500/mm³ ranged from a median of 11.5 to 13 days.
While these studies were not designed to compare survival‚ this information was collected and evaluated. The overall survival and disease progression of patients receiving NEUPOGEN® in these studies were similar to those observed in the respective control groups and to historical data.
Peripheral Blood Progenitor Cell Collection and Therapy in Cancer Patients
All patients in the Amgen-sponsored trials received a similar mobilization/collection regimen: NEUPOGEN® was administered for 6 to 7 days‚ with an apheresis procedure on days 5‚ 6, and 7 (except for a limited number of patients receiving apheresis on days 4‚ 6, and 8). In a non-Amgen-sponsored study‚ patients underwent mobilization to a target number of mononuclear cells (MNC)‚ with apheresis starting on day 5. There are no data on the mobilization of peripheral blood progenitor cells (PBPC) after days 4 to 5 that are not confounded by leukapheresis.
Mobilization of PBPC was studied in 50 heavily pretreated patients (median number of prior cycles = 9.5) with NHL‚ HD, or ALL (Amgen study 1). CFU-GM was used as the marker for engraftable PBPC. The median CFU-GM level on each day of mobilization was determined from the data available (CFU-GM assays were not obtained on all patients on each day of mobilization). These data are presented below.
The data from Amgen study 1 were supported by data from Amgen study 2 in which 22 pretreated breast cancer patients (median number of prior cycles = 3) were studied. Both the CFU-GM and CD34+ cells reached a maximum on day 5 at > 10-fold over baseline and then remained elevated with leukapheresis.
Progenitor Cell Levels in Peripheral Blood by
|Overall Study 1
CD34* (x 104/mL)
|No. Samples|| Median
(25% - 75%)
(25% - 75%)
(25% - 75%)
(13 - 62)
(15 - 151)
(0.02 - 0.66)
|Day 2||7||2 61 2-
(39 - 364)
(158 - 864)
(108 - 1819)
(0.58 - 3.93)
(391 - 1608)
(72 - 1677)
(1.08 - 6.11)
(199 - 1397)
(70 - 3486)
(1.09 - 4.40)
(111 - 938)
(118 - 2009)
(0.78 - 4.22)
(94 - 815)
(10 - 746)
(0.38 - 4.31)
|n/a = not available|
In three studies of patients with prior exposure to chemotherapy‚ the median CFU-GM yield in the leukapheresis product ranged from 20.9 to 32.7 x 104/kg body weight (n = 105). In two of these studies where CD34+ yields in the leukapheresis product were also determined‚ the median CD34+ yields were 3.11 and 2.80 x 106/kg, respectively (n = 56). In an additional study of 18 chemotherapy-naive patients‚ the median CFU-GM yield was 123.4 x 104/kg.
Engraftment following NEUPOGEN®-mobilized PBPC is summarized for 101 patients in the following table. In all studies, a Cox regression model showed that the total number of CFU-GM and/or CD34+ cells collected was a significant predictor of time to platelet recovery.
In a randomized, unblinded study of patients with HD or NHL undergoing myeloablative chemotherapy (Amgen study 3)‚ 27 patients received NEUPOGEN®-mobilized PBPC followed by NEUPOGEN® and 31 patients received ABMT followed by NEUPOGEN®. Patients randomized to the NEUPOGEN®-mobilized PBPC group compared to the ABMT group had significantly fewer days of platelet transfusions (median 6 vs 10 days)‚ a significantly shorter time to a sustained platelet count > 20‚000/mm³ (median 16 vs 23 days)‚ a significantly shorter time to recovery of a sustained ANC ≥ 500/mm³ (median 11 vs 14 days)‚ significantly fewer days of red blood cell transfusions (median 2 vs 3 days) and a significantly shorter duration of posttransplant hospitalization.
|Amgen-sponsored Study 1
N = 13
|Amgen-sponsored Study 2
N = 22
|Amgen-sponsored Study 3
N = 27
N = 39
|Median PBPC/kg Collected||MNC||9.5 x 108||9.5 x 108||8.1 x 108||10.3 x 108|
|CD34+||n/a||3.1 x 106||2.8 x 106||6.2 x 106|
|CFU-GM||63.9 x 104||25.3 x 104||32.6 x 104||n/a|
|Days to ANC > 500/mm³||Median||9||10||11||10|
|Range||8 — 10||8 — 15||9 — 38||7 — 40|
|Days to Plt. > 20,000/mm³||Median||10||12.5||16||15.5|
|Range||7 — 16||10 — 30||8 — 52||7 — 63|
|n/a = not available|
Three of the 101 patients (3%) did not achieve the criteria for engraftment as defined by a platelet count ≥ 20‚000/mm³ by day 28. In clinical trials of NEUPOGEN® for the mobilization of PBPC‚ NEUPOGEN® was administered to patients at 5 to 24 mcg/kg/day after reinfusion of the collected cells until a sustainable ANC ( ≥ 500/mm³) was reached. The rate of engraftment of these cells in the absence of NEUPOGEN® posttransplantation has not been studied.
Patients With Severe Chronic Neutropenia
Severe chronic neutropenia (SCN) (idiopathic‚ cyclic‚ and congenital) is characterized by a selective decrease in the number of circulating neutrophils and an enhanced susceptibility to bacterial infections.
The daily administration of NEUPOGEN® has been shown to be safe and effective in causing a sustained increase in the neutrophil count and a decrease in infectious morbidity in children and adults with the clinical syndrome of SCN.16 In the phase 3 trial‚ summarized in the following table‚ daily treatment with NEUPOGEN® resulted in significant beneficial changes in the incidence and duration of infection‚ fever‚ antibiotic use‚ and oropharyngeal ulcers. In this trial‚ 120 patients with a median age of 12 years (range 1 to 76 years) were treated.
Overall Significant Changes in Clinical Endpoints Median
Incidencea (events) or Duration (days) per 28-day Period
|Control Patientsb||NEUPOGEN® -treated Patients||p-value|
|Incidence of Infection||0.50||0.20||< 0.001|
|Incidence of Fever||0.25||0.20||< 0.001|
|Duration of Fever||0.63||0.20||0.005|
|Incidence of Oropharyngeal Ulcers||0.26||0.00||< 0.001|
|Incidence of Antibiotic Use||0.49||0.20||< 0.001|
|a Incidence values were calculated for each
patient‚ and are defined as the total number of events experienced divided by
the number of 28-day periods of exposure (on-study). Median incidence values
were then reported for each patient group.
b Control patients were observed for a 4-month period.
The incidence for each of these 5 clinical parameters was lower in the NEUPOGEN® arm compared to the control arm for cohorts in each of the 3 major diagnostic categories. All 3 diagnostic groups showed favorable trends in favor of treatment. An analysis of variance showed no significant interaction between treatment and diagnosis‚ suggesting that efficacy did not differ substantially in the different diseases. Although NEUPOGEN® substantially reduced neutropenia in all patient groups‚ in patients with cyclic neutropenia‚ cycling persisted but the period of neutropenia was shortened to 1 day.
As a result of the lower incidence and duration of infections‚ there was also a lower number of episodes of hospitalization (28 hospitalizations in 62 patients in the treated group vs 44 hospitalizations in 60 patients in the control group over a 4-month period [p =0.0034]). Patients treated with NEUPOGEN® also reported a lower number of episodes of diarrhea‚ nausea‚ fatigue‚ and sore throat.
In the phase 3 trial‚ untreated patients had a median ANC of 210/mm³ (range 0 to 1550/mm³). NEUPOGEN® therapy was adjusted to maintain the median ANC between 1500 and 10‚000/mm³. Overall‚ the response to NEUPOGEN® was observed in 1 to 2 weeks. The median ANC after 5 months of NEUPOGEN® therapy for all patients was 7460/mm³ (range 30 to 30‚880/mm³). NEUPOGEN® dosing requirements were generally higher for patients with congenital neutropenia (2.3 to 40 mcg/kg/day) than for patients with idiopathic (0.6 to 11.5 mcg/kg/day) or cyclic (0.5 to 6 mcg/kg/day) neutropenia.
2. Welte K‚ Bonilla MA‚ Gillio AP‚ et al. Recombinant human G-CSF: Effects on hematopoiesis in normal and cyclophosphamide treated primates. J Exp Med. 1987;165:941-948.
3. Duhrsen U‚ Villeval JL‚ Boyd J‚ et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood. 1988;72:2074-2081.
4. Souza LM‚ Boone TC‚ Gabrilove J‚ et al. Recombinant human granulocyte colonystimulating factor: Effects on normal and leukemic myeloid cells. Science. 1986;232:61-65.
5. Weisbart RH‚ Kacena A‚ Schuh A‚ Golde DW. GM-CSF induces human neutrophil IgA-mediated phagocytosis by an IgA Fc receptor activation mechanism. Nature. 1988;332:647-648.
6. Kitagawa S‚ Yuo A‚ Souza LM‚ Saito M‚ Miura Y‚ Takaku F. Recombinant human granulocyte colony-stimulating factor enhances superoxide release in human granulocytes stimulated by chemotactic peptide. Biochem Biophys Res Commun. 1987;1443:1146.
7. Glaspy JA‚ Baldwin GC‚ Robertson PA‚ et al. Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Ann Int Med. 1988;109:789-795.
8. Yuo A‚ Kitagawa S‚ Ohsaka A‚ et al. Recombinant human granulocyte colonystimulating factor as an activator of human granulocytes: Potentiation of responses triggered by receptor-mediated agonists and stimulation of C3bi receptor expression and adherence. Blood. 1989;74:2144-2149.
9. Gabrilove JL‚ Jakubowski A‚ Fain K‚ et al. Phase I study of granulocyte colonystimulating factor in patients with transitional cell carcinoma of the urothelium. J Clin Invest. 1988;82:1454-1461.
10. Morstyn G‚ Souza L‚ Keech J‚ et al. Effect of granulocyte colony-stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet. 1988;1:667-672.
11. Bronchud MH‚ Scarffe JH‚ Thatcher N‚ et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer. 1987;56:809-813.
12. Gabrilove JL‚ Jakubowski A‚ Scher H‚ et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med. 1988;318:1414-1422.
13. Neidhart J‚ Mangalik A‚ Kohler W‚ et al. Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone-marrow transplantation. J Clin Oncol. 1989;7:1685-1691.
14. Bronchud MH‚ Howell A‚ Crowther D‚ et al. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer. 1989;60:121-128.
15. Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of Filgrastim in remission induction and consolidation therapy for adults with de novo Acute Myeloid Leukemia. Blood. 1997;90:4710-4718.
16. Dale DC‚ Bonilla MA‚ Davis MW‚ et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (Filgrastim) for treatment of severe chronic neutropenia. Blood. 1993;81:2496-2502.
Last reviewed on RxList: 6/4/2012
This monograph has been modified to include the generic and brand name in many instances.
Additional Neupogen Information
Neupogen - User Reviews
Neupogen User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.